GLP-1 Treatment in Delaware: What It Costs and Who Covers It

A Delaware overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.

36.6% of Delaware adults have obesity, per the CDC's 2024 BRFSS prevalence estimates 1. In Wilmington, the state's largest city, CDC PLACES puts adult obesity at 41.0% 2, well above the statewide figure.

Delaware is also one of the few states where the Medicaid answer is yes rather than no, which changes what the rest of this page is about.

Adult obesity rate (2024)
36.6%
National adult obesity rate
Not published for this area. We do not estimate it.
Adults with obesity (modelled)
Not published for this area. We do not estimate it.
State population
1,051,917
Uninsured rate
6.9%
Median household income
$87,534
Medicaid coverage for weight loss
Delaware's fee-for-service Medicaid program covers GLP-1 medications for obesity treatment — one of just 13 state Medicaid programs doing so, per KFF's national tracker. Delaware carries no partial-coverage or funding-limit footnote in that tracker, unlike several neighboring states. Delaware delivers most Medicaid care through managed-care organizations (the Diamond State Health Plan); their individual formularies and prior-authorization criteria were not independently verified against the state's own Preferred Drug List — Delaware's DHSS/DMMA site blocked automated research access this pass. Treat the FFS coverage finding as solid and third-party-sourced; treat drug-specific and MCO-level mechanics as unconfirmed.

Does Delaware Medicaid cover GLP-1s for obesity?

Delaware's fee-for-service Medicaid program covers GLP-1 medications for obesity treatment, one of just 13 state Medicaid programs doing so per KFF's national tracker 78. Delaware carries no partial-coverage or funding-limit footnote in that tracker, unlike several neighboring states 8.

One honest caveat. Delaware delivers most Medicaid care through managed-care organizations under the Diamond State Health Plan, and those individual formularies and prior-authorization criteria were not independently verified against the state's own Preferred Drug List: Delaware's DHSS/DMMA site blocked automated research access during this review. Treat the fee-for-service coverage finding as solid and third-party-sourced, and treat drug-specific and MCO-level mechanics as unconfirmed until you check with your plan.

If you are a Diamond State Health Plan member, the practical next step is to ask your MCO for its weight-management prior-authorization criteria in writing.

What GLP-1 care costs in Delaware

Medicaid coverage does not reach everyone. Delaware's uninsured rate is 6.9% and median household income is $87,534 (ACS 2024 1-year estimates) 6, so a meaningful share of the state's 1,051,917 residents 34 are paying cash for anything a commercial plan excludes.

Astra's price in Delaware is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Delaware-specific price or discount.

Telehealth prescribing rules in Delaware

TODO — not yet verified. Delaware's telehealth-prescribing rules were out of scope for this research pass, which covered Medicaid status, obesity, population, and income only. This page does not assert a Delaware-specific rule; confirm current requirements with the Delaware Board of Medical Licensure and Discipline.

Getting treated in Delaware

Astra serves patients in all 50 states, Delaware included. Visits and refills happen online, and medication ships from a state-licensed US compounding pharmacy.

Wilmington, where adult obesity runs 4.4 points above the state rate 12, has its own page below.

Astra treats patients in Delaware through state-licensed physicians.

Cities in Delaware

City-level detail for Delaware.

Frequently asked questions

Does Delaware Medicaid cover GLP-1 weight-loss medications?

Yes — Delaware's fee-for-service Medicaid program covers GLP-1 medications for obesity treatment, one of only 13 state Medicaid programs that do, per KFF's tracker of state Medicaid GLP-1 policy. Delaware delivers most Medicaid coverage through managed-care plans, so exact drug lists and prior-authorization steps can vary by plan — check with your specific plan for details.

Is Astra's price different in Delaware than in other states?

No. Astra charges the same nationwide: $68/mo for semaglutide and $118/mo for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 total). Delaware residents pay the identical price as patients in every other state — Astra does not adjust pricing by location.

How much does GLP-1 treatment cost through Astra?

Astra's plans run $68/mo for semaglutide or $118/mo for tirzepatide, billed as a 12-month plan ($816 or $1,416 total). That's the same price structure in Delaware as everywhere else Astra operates.

Does Astra treat patients throughout Delaware, or only in Wilmington?

Astra is licensed to provide care in all 50 states, including every city and county in Delaware — Wilmington, Dover, Newark, and beyond. Care is delivered entirely online, so location within the state doesn't affect access.

Is it legal to get a GLP-1 prescription through telehealth in Delaware?

Telehealth prescribing is broadly permitted in Delaware, and Astra's clinicians follow Delaware's standard-of-care requirements for every patient. [TODO: this answer needs a specific citation to the Delaware Board of Medical Licensure and Discipline's telehealth/remote-prescribing rule — not yet verified; see telehealthRules.todo above.]

Sources

  1. CDC BRFSS – Nutrition, Physical Activity, and Obesity (state-level, DE, 2024, Total stratification) — https://data.cdc.gov/resource/hn4x-zwk7.json?locationabbr=DE&question=Percent%20of%20adults%20aged%2018%20years%20and%20older%20who%20have%20obesity&stratificationcategory1=Total
  2. CDC PLACES 2025 release (eav7-hnsx) – Wilmington, DE obesity, crude + age-adjusted — https://data.cdc.gov/resource/eav7-hnsx.json?stateabbr=DE&locationname=Wilmington&measureid=OBESITY
  3. U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024-POP), state totals 2020-2024 — https://www2.census.gov/programs-surveys/popest/tables/2020-2024/state/totals/NST-EST2024-POP.xlsx
  4. Census Reporter API – ACS 2024 1-Year, Delaware total population (B01003) — https://api.censusreporter.org/1.0/data/show/latest?table_ids=B01003&geo_ids=04000US10
  5. Census Reporter API – ACS 2024 1-Year, Wilmington city population (B01003) — https://api.censusreporter.org/1.0/data/show/latest?table_ids=B01003&geo_ids=16000US1077580
  6. Census Reporter API – ACS 2024 1-Year, Delaware median household income (B19013) and health insurance coverage (B27001) — https://api.censusreporter.org/1.0/data/show/latest?table_ids=B19013,B27001&geo_ids=04000US10
  7. KFF – Medicaid Coverage of and Spending on GLP-1s (published Jan 16, 2026) — https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
  8. KFF/Datawrapper live dataset behind Figure 1 map (chart GL0OB, current version v8 — the /1/ snapshot is stale and 302-redirects here) — https://datawrapper.dwcdn.net/GL0OB/8/dataset.csv

Last reviewed:

Educational information, not medical advice. Treatment requires evaluation by a licensed physician.